Angina
Company launches phase IIb trial in patients with severe coronary artery disease
Published in Biotech Business Week, March 28th, 2005
The NOVA (NOGA Delivery of VEGF for Angina) trial will evaluate the effects of BIOBYPASS on exercise tolerance, heart function, symptoms, and quality of life in approximately 129 patients suffering from moderate-to-severe chest pain due to advanced coronary artery disease.
Jens Kastrup, MD, at Rigshospitalet in Copenhagen, Denmark, is the principal investigator for the NOVA trial. Two medical centers have begun enrollment, under the direction of Dr. Erik Jorgensen at...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Cancer Therapy
Inherited traits, tumor mutations affect response to Treatment of ALL - Cardiovascular Research
Enrollment completed in trial for paclitaxel-eluting coronary stent system - Diagnostics
FDA grants clearance to market drug screens with acetaminophen - HIV/AIDS
Antibody that neutralizes most HIV strains described - Hip Replacement
Cost savings, better outcomes noted in hip technique study - Addiction Medicine
Injection drug use status influences HCV-related referral and treatment - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
